Update on the latest in PARP inhibitors for prostate cancer

Bookmark and Share
Published: 11 Jul 2022
Views: 1150
Rating:
Save
Prof Axel Merseburger and Prof Bertrand Tombal

Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) and Prof Bertrand Tombal (Université Catholique de Louvain, Brussels, Belgium) discuss the latest in PARP inhibitors for prostate cancer.

Initially, Prof Tombal comments on the phase III PROpel trial which investigated the tolerability of abiraterone combined with olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

Prof Merseburger and Prof Tombal also discuss the health-related quality of life and pain in the MAGNITUDE study of niraparib with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

They discuss what this data could mean for the future treatment of prostate cancer.

Prom Tombal then gives practical guidance on testing for HRR mutations. They also cover other subgroup analysis studies from EAU 2022 that investigated BRCAness and PARP inhibitors.

They conclude by talking about the PRESIDE trial.

 

This programme has been supported by an unrestricted educational grant from AstraZeneca.